cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.15468/dl.bkdmfj
title: Occurrence Download

description: A dataset containing 88 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is Asia",
 "Country is China",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "TaxonKey is Draba glomerata",
 "Year 1970-2000"
 ]
}

 The dataset includes 88 records from 7 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0074176-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.a353ja
title: Occurrence Download

description: A dataset containing 3758 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "GadmGid is CHN.13.3_1",
 "OccurrenceStatus is Present",
 "Year 2000-2024"
 ]
}

 The dataset includes 3758 records from 58 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0074179-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.7gm3h4
title: Occurrence Download

description: A dataset listing the 87 species recorded in GBIF matching the query:
{
 "and" : [
 "Geometry POLYGON((-69.47152 48.62117,-68.28326 48.09592,-64.79596 48.92254,-65.04566 48.19064,-65.29537 46.85599,-64.21904 45.98632,-63.14272 45.59023,-60.71452 45.81411,-58.72547 47.64817,-58.26911 51.42823,-68.4813 50.6791,-69.47152 48.62117))",
 "TaxonKey is one of (Pseudo-nitzschia, Bacillariophyceae)"
 ]
}

 The dataset's 87 records were derived from 10 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0074173-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30277600
title: Current trends and future artificial intelligence applications in transfusion medicine: a bibliometric analysis

description: Artificial Intelligence (AI) is increasingly vital in transfusion medicine for enhancing service quality and efficiency. However, bibliometric studies in this area are scarce. This analysis maps current and emerging research trends. Publications from 1 January 2000 to 31 August 2025, were retrieved from the Web of Science Core Collection. VOSviewer, CiteSpace, and Excel were used to visualize contributions and trends across authors, institutions, journals, and countries. Among 159 publications, the U.S.A. China, and India led in output. The University of Colorado was the top institution, while Transfusion had the highest citations. Axel Hofmann was the most cited author. Keywords such as ‘machine learning’ and ‘deep learning’ highlight the rapid adoption of advanced AI technologies. This study outlines current trends and emerging frontiers, offering valuable insights and guidance for future AI applications in transfusion medicine.
DOI: 10.6084/m9.figshare.30277600.v2
title: Current trends and future artificial intelligence applications in transfusion medicine: a bibliometric analysis

description: Artificial Intelligence (AI) is increasingly vital in transfusion medicine for enhancing service quality and efficiency. However, bibliometric studies in this area are scarce. This analysis maps current and emerging research trends. Publications from 1 January 2000 to 31 August 2025, were retrieved from the Web of Science Core Collection. VOSviewer, CiteSpace, and Excel were used to visualize contributions and trends across authors, institutions, journals, and countries. Among 159 publications, the U.S.A. China, and India led in output. The University of Colorado was the top institution, while Transfusion had the highest citations. Axel Hofmann was the most cited author. Keywords such as ‘machine learning’ and ‘deep learning’ highlight the rapid adoption of advanced AI technologies. This study outlines current trends and emerging frontiers, offering valuable insights and guidance for future AI applications in transfusion medicine.
DOI: 10.6084/m9.figshare.30231152
title: Safety and efficacy of non-first-line drugs in the treatment of immune thrombocytopenia: a systematic review and network meta-analysis

description: This systematic review and network meta-analysis(NMA) comprehensively evaluated the efficacy and safety of non-first-line drugs in the treatment of adult patients with immune thrombocytopenia (ITP). PubMed, Web of Science, Embase, and the Cochrane Library were systematically searched. Randomized controlled trials (RCTs) investigating Count data were extracted in the form of event occurrences/non-occurrences. NMA was carried out via R. 29 RCTs were encompassed. In contrast to placebo, the avatrombopag 20 mg group demonstrated the highest PR (RR = 12.23, 95% CrI: 5.48–33.72). The combination of eltrombopag and danazol exhibited the lowest incidence of bleeding events (RR = 0.31, 95% CrI: 0.16–0.57), while the avatrombopag 5 mg group had the lowest incidence of SAEs (RR = 0.44, 95% CrI: 0.22–0.84). The comprehensive evaluation suggested that romiplostim, initiated at a dose of 1 μg/kg within a dose-adjustment regimen, may confer one of the most favorable benefit – risk profiles, with a relatively high PR (SUCRA = 75.1%) and a low incidence of bleeding events (SUCRA = 54.8%). When initiating therapy with romiplostim at a dose of 1 μg/kg and subsequently titrating the dosage according to the patient’s platelet response, romiplostim may represent one of the most effective therapeutic options. The study protocol for this systematic review was registered in the International Prospective Registry of Systematic Reviews (PROSPERO) database (http://www.crd.york.ac.uk/prospero/), and it was allocated the PROSPERO identification number
DOI: 10.6084/m9.figshare.30231152.v1
title: Safety and efficacy of non-first-line drugs in the treatment of immune thrombocytopenia: a systematic review and network meta-analysis

description: This systematic review and network meta-analysis(NMA) comprehensively evaluated the efficacy and safety of non-first-line drugs in the treatment of adult patients with immune thrombocytopenia (ITP). PubMed, Web of Science, Embase, and the Cochrane Library were systematically searched. Randomized controlled trials (RCTs) investigating Count data were extracted in the form of event occurrences/non-occurrences. NMA was carried out via R. 29 RCTs were encompassed. In contrast to placebo, the avatrombopag 20 mg group demonstrated the highest PR (RR = 12.23, 95% CrI: 5.48–33.72). The combination of eltrombopag and danazol exhibited the lowest incidence of bleeding events (RR = 0.31, 95% CrI: 0.16–0.57), while the avatrombopag 5 mg group had the lowest incidence of SAEs (RR = 0.44, 95% CrI: 0.22–0.84). The comprehensive evaluation suggested that romiplostim, initiated at a dose of 1 μg/kg within a dose-adjustment regimen, may confer one of the most favorable benefit – risk profiles, with a relatively high PR (SUCRA = 75.1%) and a low incidence of bleeding events (SUCRA = 54.8%). When initiating therapy with romiplostim at a dose of 1 μg/kg and subsequently titrating the dosage according to the patient’s platelet response, romiplostim may represent one of the most effective therapeutic options. The study protocol for this systematic review was registered in the International Prospective Registry of Systematic Reviews (PROSPERO) database (http://www.crd.york.ac.uk/prospero/), and it was allocated the PROSPERO identification number
DOI: 10.6084/m9.figshare.30277600.v1
title: Current trends and future artificial intelligence applications in transfusion medicine: a bibliometric analysis

description: Artificial Intelligence (AI) is increasingly vital in transfusion medicine for enhancing service quality and efficiency. However, bibliometric studies in this area are scarce. This analysis maps current and emerging research trends. Publications from 1 January 2000 to 31 August 2025, were retrieved from the Web of Science Core Collection. VOSviewer, CiteSpace, and Excel were used to visualize contributions and trends across authors, institutions, journals, and countries. Among 159 publications, the U.S.A. China, and India led in output. The University of Colorado was the top institution, while Transfusion had the highest citations. Axel Hofmann was the most cited author. Keywords such as ‘machine learning’ and ‘deep learning’ highlight the rapid adoption of advanced AI technologies. This study outlines current trends and emerging frontiers, offering valuable insights and guidance for future AI applications in transfusion medicine.
DOI: 10.6084/m9.figshare.30351379
title: May obesity increase the risk of lymphoma? Insights from genetic evidence

description: Lymphoma poses a significant public health challenge with complex subtypes. While obesity and adipokines have been linked to lymphoma, causal relationships remain unclear. This study uses Mendelian randomization (MR) to systematically assess these associations. Two-sample MR analyzed genetic data from genome-wide association studies to evaluate causal links between obesity, adipokines (adiponectin, leptin, and resistin), and lymphoma subtypes (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Hodgkin lymphoma, and other unspecified types of non-Hodgkin lymphoma). Primary analysis used inverse variance weighted (IVW), supported by MR-Egger, weighted median, and weighted mode methods. Sensitivity analyses (MR-Egger regression, Cochran’s Q test, MR-PRESSO, leave-one-out) and linkage disequilibrium score regression (LDSC) ensured robustness. IVW revealed obesity positively associated with follicular lymphoma (OR = 1.352, 95% CI: 1.095–1.670, <i>p</i> = 0.005) and other unspecified types of non-Hodgkin lymphoma (OR = 1.297, 95% CI: 1.050–1.603, <i>p</i> = 0.016). No significant links were found between adipokines and lymphoma. Sensitivity analyses confirmed no heterogeneity or pleiotropy. Obesity may independently increase lymphoma risk, unrelated to adipokines. These findings highlight new risk factors, urging further research into pathological mechanisms and biomarkers.
DOI: 10.6084/m9.figshare.30351379.v2
title: May obesity increase the risk of lymphoma? Insights from genetic evidence

description: Lymphoma poses a significant public health challenge with complex subtypes. While obesity and adipokines have been linked to lymphoma, causal relationships remain unclear. This study uses Mendelian randomization (MR) to systematically assess these associations. Two-sample MR analyzed genetic data from genome-wide association studies to evaluate causal links between obesity, adipokines (adiponectin, leptin, and resistin), and lymphoma subtypes (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Hodgkin lymphoma, and other unspecified types of non-Hodgkin lymphoma). Primary analysis used inverse variance weighted (IVW), supported by MR-Egger, weighted median, and weighted mode methods. Sensitivity analyses (MR-Egger regression, Cochran’s Q test, MR-PRESSO, leave-one-out) and linkage disequilibrium score regression (LDSC) ensured robustness. IVW revealed obesity positively associated with follicular lymphoma (OR = 1.352, 95% CI: 1.095–1.670, <i>p</i> = 0.005) and other unspecified types of non-Hodgkin lymphoma (OR = 1.297, 95% CI: 1.050–1.603, <i>p</i> = 0.016). No significant links were found between adipokines and lymphoma. Sensitivity analyses confirmed no heterogeneity or pleiotropy. Obesity may independently increase lymphoma risk, unrelated to adipokines. These findings highlight new risk factors, urging further research into pathological mechanisms and biomarkers.
DOI: 10.6084/m9.figshare.30351379.v1
title: May obesity increase the risk of lymphoma? Insights from genetic evidence

description: Lymphoma poses a significant public health challenge with complex subtypes. While obesity and adipokines have been linked to lymphoma, causal relationships remain unclear. This study uses Mendelian randomization (MR) to systematically assess these associations. Two-sample MR analyzed genetic data from genome-wide association studies to evaluate causal links between obesity, adipokines (adiponectin, leptin, resistin), and lymphoma subtypes (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, Hodgkin lymphoma and other unspecified types of non-Hodgkin lymphoma). Primary analysis used inverse variance weighted (IVW), supported by MR-Egger, weighted median, and weighted mode methods. Sensitivity analyses (MR-Egger regression, Cochran’s Q test, MR-PRESSO, leave-one-out) and linkage disequilibrium score regression (LDSC) ensured robustness. IVW revealed obesity positively associated with follicular lymphoma (OR = 1.352, 95%CI: 1.095–1.670, <i>p</i> = 0.005) and other unspecified types of non-Hodgkin lymphoma (OR = 1.297, 95%CI: 1.050–1.603, <i>p</i> = 0.016). No significant links were found between adipokines and lymphoma. Sensitivity analyses confirmed no heterogeneity or pleiotropy. Obesity may independently increase lymphoma risk, unrelated to adipokines. These findings highlight new risk factors, urging further research into pathological mechanisms and biomarkers.
DOI: 10.6084/m9.figshare.30370694
title: Efficacy and safety of EGFR monoclonal antibody combined with gemcitabine-based chemotherapy in first-line treatment of locally advanced unresectable or metastatic pancreatic cancer

description: The prognosis for patients with advanced pancreatic cancer (PC) remains extremely poor, underscoring the critical need to explore and optimize systemic treatment strategies. This study aimed to evaluate the efficacy and safety of combining EGFR monoclonal antibodies (Anti-EGFR-mAb) with gemcitabine-based chemotherapy as a first-line treatment for locally advanced or metastatic PC. A total of 11 studies were included, with a total sample size of 806 patients with locally advanced or metastatic PC. Meta-analysis results showed that the objective response rate (ORR) for first-line treatment of advanced PC with Anti-EGFR-mAb combined with gemcitabine was 15% (95% CI: 10–22%), and the disease control rate (DCR) was 58% (95% CI: 49–67%). Compared with gemcitabine-based chemotherapy, combination therapy did not improve progression-free time (PFS) (HR = 0.93, 95%CI: 0.81–1.04, <i>p</i> = 0.057) or overall survival (OS) (HR = 0.90, 95%CI: 0.78–1.02, <i>p</i> = 0.04). The incidence of severe adverse events (sAEs) caused by combination therapy was 31% (95% CI: 14–50%). Anti-EGFR-mAb combined with gemcitabine chemotherapy has shown a good efficacy to first-line treatment of advanced PC, it did not provide a significant survival benefit compared to chemotherapy alone. Additionally, combination therapy was associated with a high incidence of AEs, highlighting safety concerns that warrant special attention. PROSPERO (CRD420250652874).
DOI: 10.6084/m9.figshare.30370694.v1
title: Efficacy and safety of EGFR monoclonal antibody combined with gemcitabine-based chemotherapy in first-line treatment of locally advanced unresectable or metastatic pancreatic cancer

description: The prognosis for patients with advanced pancreatic cancer (PC) remains extremely poor, underscoring the critical need to explore and optimize systemic treatment strategies. This study aimed to evaluate the efficacy and safety of combining EGFR monoclonal antibodies (Anti-EGFR-mAb) with gemcitabine-based chemotherapy as a first-line treatment for locally advanced or metastatic PC. A total of 11 studies were included, with a total sample size of 806 patients with locally advanced or metastatic PC. Meta-analysis results showed that the objective response rate (ORR) for first-line treatment of advanced PC with Anti-EGFR-mAb combined with gemcitabine was 15% (95% CI: 10–22%), and the disease control rate (DCR) was 58% (95% CI: 49–67%). Compared with gemcitabine-based chemotherapy, combination therapy did not improve progression-free time (PFS) (HR = 0.93, 95%CI: 0.81–1.04, <i>p</i> = 0.057) or overall survival (OS) (HR = 0.90, 95%CI: 0.78–1.02, <i>p</i> = 0.04). The incidence of severe adverse events (sAEs) caused by combination therapy was 31% (95% CI: 14–50%). Anti-EGFR-mAb combined with gemcitabine chemotherapy has shown a good efficacy to first-line treatment of advanced PC, it did not provide a significant survival benefit compared to chemotherapy alone. Additionally, combination therapy was associated with a high incidence of AEs, highlighting safety concerns that warrant special attention. PROSPERO (CRD420250652874).
DOI: 10.6084/m9.figshare.30404362
title: A clinical visualization model for predicting distant metastasis and prognostic outcomes in mucinous adenocarcinoma of the appendix: a SEER database study

description: Mucinous adenocarcinoma of the appendix (MACA) has high metastatic potential and poor prognosis, lacking predictive models. This study aimed to establish models for assessing distant metastasis (DM) risk and survival prognosis of MACA patients with DM. SEER database data of MACA patients diagnosed from 2010 to 2021 were collected. Univariate and multivariate logistic regression identified DM risk factors, while Cox regression determined prognostic factors for DM patients. Two nomograms were created and evaluated via ROC curves, calibration curves, and DCA. Results: A total of 1722 patients with MACA were included, and 832 patients had DM at the time of diagnosis. The independent risk factors for DM in patients with MACA include gender, age, tumor size, T stage, and N stage. For MACA patients with DM, age, N stage, and surgical treatment were independent risk factors for overall survival (OS). The diagnostic and prognostic nomograms showed good discriminatory ability and calibration. The independent prognostic factors for MACA patients with DM are age, N stage, and surgery. The established diagnostic and prognostic models can quantitatively assess the risk and prognosis of MACA with DM, providing more effective guidance for clinical decision-making.
DOI: 10.6084/m9.figshare.30404362.v2
title: A clinical visualization model for predicting distant metastasis and prognostic outcomes in mucinous adenocarcinoma of the appendix: a SEER database study

description: Mucinous adenocarcinoma of the appendix (MACA) has high metastatic potential and poor prognosis, lacking predictive models. This study aimed to establish models for assessing distant metastasis (DM) risk and survival prognosis of MACA patients with DM. SEER database data of MACA patients diagnosed from 2010 to 2021 were collected. Univariate and multivariate logistic regression identified DM risk factors, while Cox regression determined prognostic factors for DM patients. Two nomograms were created and evaluated via ROC curves, calibration curves, and DCA. Results: A total of 1722 patients with MACA were included, and 832 patients had DM at the time of diagnosis. The independent risk factors for DM in patients with MACA include gender, age, tumor size, T stage, and N stage. For MACA patients with DM, age, N stage, and surgical treatment were independent risk factors for overall survival (OS). The diagnostic and prognostic nomograms showed good discriminatory ability and calibration. The independent prognostic factors for MACA patients with DM are age, N stage, and surgery. The established diagnostic and prognostic models can quantitatively assess the risk and prognosis of MACA with DM, providing more effective guidance for clinical decision-making.
DOI: 10.6084/m9.figshare.30404362.v1
title: A clinical visualization Model for predicting distant metastasis and prognostic outcomes in Mucinous adenocarcinoma of the appendix: a SEER database study

description: Mucinous adenocarcinoma of the appendix (MACA) has high metastatic potential and poor prognosis, lacking predictive models. This study aimed to establish models for assessing distant metastasis (DM) risk and survival prognosis of MACA patients with DM. SEER database data of MACA patients diagnosed from 2010 to 2021 were collected. Univariate and multivariate logistic regression identified DM risk factors, while Cox regression determined prognostic factors for DM patients. Two nomograms were created and evaluated via ROC curves, calibration curves, and DCA.Results: A total of 1722 patients with MACA were included, and 832 patients had DM at the time of diagnosis. The independent risk factors for DM in patients with MACA include gender, age, tumor size, T stage, and N stage. For MACA patients with DM, age, N stage and surgical treatment were independent risk factors for overall survival (OS). The diagnostic and prognostic nomograms showed good discriminatory ability and calibration. The independent prognostic factors for MACA patients with DM are age, N stage and surgery. The established diagnostic and prognostic models can quantitatively assess the risk and prognosis of MACA with DM, providing more effective guidance for clinical decision making.
DOI: 10.15468/dl.npq4w4
title: Occurrence Download

description: A dataset containing 10002 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is China",
 "GadmGid is CHN.13.14_1",
 "OccurrenceStatus is Present",
 "Year 2000-2024"
 ]
}

 The dataset includes 10002 records from 26 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0074180-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.cahtnm
title: Occurrence Download

description: A dataset containing 373616 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is one of (Capsella bursa-pastoris)",
 "Year is greater than or equal to 2000",
 "Year is less than or equal to 2025",
 "HasCoordinate is true",
 "HasGeospatialIssue is false"
 ]
}

 The dataset includes 373616 records from 2476 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0074165-251120083545085/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.wdwtvj
title: Occurrence Download

description: A dataset containing 1 species occurrences available in GBIF matching the query:
{
 "and" : [
 "TaxonKey is Typhaeus hiostius Gene, 1836",
 "HasCoordinate is true",
 "HasGeospatialIssue is false",
 "OccurrenceStatus is Present"
 ]
}

 The dataset includes 1 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006417-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.cuqukd
title: Occurrence Download

description: A dataset containing 362 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Country is United Kingdom of Great Britain and Northern Ireland",
 "DatasetKey is iNaturalist Research-grade Observations",
 "OccurrenceStatus is Present",
 "TaxonKey is Stachys byzantina K.Koch",
 "Year 2014-2024"
 ]
}

 The dataset includes 362 records from 1 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006419-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.pun5ew
title: Occurrence Download

description: A dataset containing 470 species occurrences available in GBIF matching the query:
{
 "and" : [
 "HasGeospatialIssue is false",
 "HasCoordinate is true",
 "OccurrenceStatus is Present",
 {
 "not" : {
 "BasisOfRecord" : [
 "is one of (Fossil, Living Specimen)"
 ]
 }
 },
 "TaxonKey is one of (Exbucklandia populnea (R.Br. ex Griff.) R.W.Br.)"
 ]
}

 The dataset includes 470 records from 33 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0006420-241126133413365/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.